New hope for back pain: experimental drug LNK01001 enters final trial phase
Disease control
Recruiting now
This study tests whether the experimental drug LNK01001 can reduce pain and stiffness in adults with active ankylosing spondylitis, a type of arthritis that mainly affects the spine. About 352 participants will receive either LNK01001 or a placebo twice daily for 16 weeks, then e…
Phase: PHASE3 • Sponsor: Lynk Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC